New pharmacological developments in the treatment of hepatocellular cancer

Drugs

Volumn 69, Issue 18, 2009, Pages 2533-2540

  Gusani, Niraj J ^a   Jiang, Yixing ^a   Kimchi, Eric T ^a   Staveley O'Carroll, Kevin F ^a   Cheng, Hua ^a   Ajani, Jaffer A ^b  

^a PENN STATE CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 (3 AMINO 1H INDAZOL 4 YL)PHENYL] 3 (2 FLUORO 5 METHYLPHENYL)UREA; 5 (4 BROMO 2 CHLOROANILINO) 4 FLUORO 1 METHYL 1H BENZIMIDAZOLE 6 CARBOHYDROXAMIC ACID 2 HYDROXYETHYL ESTER; ALPHA INTERFERON; AMG 386; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB ALANINATE; CETUXIMAB; CISPLATIN; CIXUTUMUMAB; DASATINIB; DOXORUBICIN; ERLOTINIB; EVEROLIMUS; FLUOROURACIL; GEFITINIB; GEMCITABINE; IMATINIB; IMC 1121B; IMC A12; LAPATINIB; LINIFANIB; NOLATREXED; OXALIPLATIN; PAZOPANIB; PLACEBO; RAMUCIRUMAB; RAPAMYCIN; SORAFENIB; SUNITINIB; THALIDOMIDE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

BREAST CANCER; CANCER CHEMOTHERAPY; CANCER MORTALITY; CANCER SCREENING; CANCER STAGING; CANCER SURGERY; CANCER SURVIVAL; CHEMOEMBOLIZATION; CLINICAL TRIAL; COLORECTAL CANCER; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL STROMAL TUMOR; HUMAN; INTERVENTION STUDY; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LUNG CANCER; NONHUMAN; PATHOGENESIS; RADIOFREQUENCY ABLATION; REVIEW; TUMOR NECROSIS; UNITED STATES;

ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BENZENESULFONATES; BREAST NEOPLASMS; CARCINOMA, HEPATOCELLULAR; CHEMOEMBOLIZATION, THERAPEUTIC; COMBINED MODALITY THERAPY; DRUG DELIVERY SYSTEMS; DRUG DESIGN; DRUG RESISTANCE, NEOPLASM; HUMANS; LIVER NEOPLASMS; META-ANALYSIS AS TOPIC; PATIENT SELECTION; PROTEIN KINASE INHIBITORS; PYRIDINES; RECEPTOR, EPIDERMAL GROWTH FACTOR; RISK ASSESSMENT; SEVERITY OF ILLNESS INDEX; SIGNAL TRANSDUCTION; TREATMENT OUTCOME; VASCULAR ENDOTHELIAL GROWTH FACTOR A;

EID: 71849115391     PISSN: 00126667     EISSN: 11791950     Source Type: Journal    
DOI: 10.2165/11530870-000000000-00000     Document Type: Review

References (64)

1. El-Serag HB, Mason AC. Rising incidence of hepatocellular carcinoma in the United States. N Engl J Med 1999 Mar 11; 340 (10): 745-750
2. Llovet JM. Updated treatment approach to hepatocellular carcinoma. J Gastroenterol 2005 Mar; 40 (3): 225-235
3. Iwatsuki S, Starzl TE, Sheahan DG, et al. Hepatic resection versus transplantation for hepatocellular carcinoma. Ann Surg 1991 Sep; 214 (3): 221-28; discussion 8-9.
4. Fong Y, Sun RL, Jarnagin W, et al. An analysis of 412 cases of hepatocellular carcinoma at a Western center. Ann Surg 1999 Jun; 229 (6): 790-9; discussion 9-800.
5. Poon RT, Fan ST, Lo CM, et al. Improving survival results after resection of hepatocellular carcinoma: a prospective study of 377 patients over 10 years. Ann Surg 2001 Jul; 234 (1): 63-70.
6. Sala M, Fuster J, Llovet JM, et al. High pathological risk of recurrence after surgical resection for hepatocellular carcinoma: an indication for salvage liver transplantation. Liver Transpl 2004 Oct; 10 (10): 1294-1300
7. Fausto N, Laird AD, Webber EM. Liver regeneration 2: role of growth factors and cytokines in hepatic regeneration. FASEB J 1995 Dec; 9 (15): 1527-1536
8. Inui Y, Higashiyama S, Kawata S, et al. Expression of heparin-binding epidermal growth factor in human hepatocellular carcinoma. Gastroenterology 1994 Dec; 107 (6): 1799-1804 (Pubitemid 24357636)
9. Kiss A, Wang NJ, Xie JP, et al. Analysis of transforming growth factor (TGF)-alpha/epidermal growth factor receptor, hepatocyte growth Factor/c-met,TGF-beta receptor type II, and p53 expression in human hepatocellular carcinomas. Clin Cancer Res 1997 Jul; 3 (7): 1059-1066
10. Kaneko Y, Shibuya M, Nakayama T, et al. Hypomethyla-tion of c-myc and epidermal growth factor receptor genes in human hepatocellular carcinoma and fetal liver. Jpn J Cancer Res 1985 Dec; 76 (12): 1136-1140
11. Yamaguchi K, Carr BI, Nalesnik MA. Concomitant and isolated expression of TGF-alpha and EGF-R in human hepatoma cells supports the hypothesis of autocrine, paracrine, and endocrine growth of human hepatoma. J Surg Oncol 1995 Apr; 58 (4): 240-245
12. Morimitsu Y, Hsia CC, Kojiro M, et al. Nodules of less-differentiated tumor within or adjacent to hepatocellular carcinoma: relative expression of transforming growth factor-alpha and its receptor in the different areas of tumor. Hum Pathol 1995 Oct; 26 (10): 1126-1132
13. Mise M, Arii S, Higashituji H, et al. Clinical significance of vascular endothelial growth factor and basic fibroblast growth factor gene expression in liver tumor. Hepatology 1996 Mar; 23 (3): 455-464
14. Suzuki K, Hayashi N, Miyamoto Y, et al. Expression of vascular permeability factor/vascular endothelial growth factor in human hepatocellular carcinoma. Cancer Res 1996 Jul 1; 56 (13): 3004-3009
15. Yamaguchi R, Yano H, Iemura A, et al. Expression of vas-cular endothelial growth factor in human hepatocellular carcinoma. Hepatology 1998 Jul; 28 (1): 68-77.
16. Miura H, Miyazaki T, Kuroda M, et al. Increased expres-sion of vascular endothelial growth factor in human he-patocellular carcinoma. J Hepatol 1997 Nov; 27 (5): 854-861 (Pubitemid 27454829)
17. An FQ, Matsuda M, Fujii H, et al. Expression of vascular endothelial growth factor in surgical specimens of hepato-cellular carcinoma. J Cancer Res Clin Oncol 2000 Mar; 126 (3): 153-160
18. Jinno K, Tanimizu M, Hyodo I, et al. Circulating vascular endothelial growth factor (VEGF) is a possible tumor marker for metastasis in human hepatocellular carcinoma. J Gastroenterol 1998 Jun; 33 (3): 376-382
19. Li XM, Tang ZY, Zhou G, et al. Significance of vascular endothelial growth factor mRNA expression in invasion and metastasis of hepatocellular carcinoma. J Exp Clin Cancer Res 1998 Mar; 17 (1): 13-17
20. Colnot S, Decaens T, Niwa-Kawakita M, et al. Liver-targeted disruption of Apc in mice activates beta-catenin signaling and leads to hepatocellular carcinomas. Proc Natl Acad Sci U S A 2004 Dec 7; 101 (49): 17216-17221
21. Schmitz KJ, Wohlschlaeger J, Lang H, et al. Activation of the ERK and AKT signalling pathway predicts poor prognosis in hepatocellular carcinoma and ERK activation in cancer tissue is associated with hepatitis C virus infection. J Hepatol 2008 Jan; 48 (1): 83-90.
22. Chin R, Earnest-Silveira L, Koeberlein B, et al. Modulation of MAPK pathways and cell cycle by replicating hepatitis B virus: factors contributing to hepatocarcinogenesis. J Hepatol 2007 Sep; 47 (3): 325-337
23. Terris B, Pineau P, Bregeaud L, et al. Close correlation be-tween beta-catenin gene alterations and nuclear accumulation of the protein in human hepatocellular carcinomas. Oncogene 1999 Nov 11; 18 (47): 6583-6588
24. Cotler SJ, Hay N, Xie H, et al. Immunohistochemical ex-pression of components of the Akt-mTORC1 pathway is associated with hepatocellular carcinoma in patients with chronic liver disease. Dig Dis Sci 2008 Mar; 53 (3): 844-849
25. Hsu IC, Metcalf RA, Sun T, et al. Mutational hotspot in the p53 gene in human hepatocellular carcinomas. Nature 1991 Apr 4; 350 (6317): 427-428
26. Challen C, Guo K, Collier JD, et al. Infrequent point muta-tions in codons 12 and 61 of ras oncogenes in human hepa-tocellular carcinomas. J Hepatol 1992 Mar; 14 (2-3): 342-346
27. Cerutti P, Hussain P, Pourzand C, et al. Mutagenesis of the H-ras protooncogene and the p53 tumor suppressor gene. Cancer Res 1994 Apr 1; 54 (7 Suppl.): 1934-8s.
28. Bai F, Nakanishi Y, Takayama K, et al. Codon 64 of K-ras gene mutation pattern in hepatocellular carcinomas induced by bleomycin and 1-nitropyrene in A/J mice. Teratog Carcinog Mutagen 2003; Suppl. 1: 161-170
29. Lee JS, Heo J, Libbrecht L, et al. A novel prognostic subtype of human hepatocellular carcinoma derived from hepatic progenitor cells. Nat Med 2006 Apr; 12 (4): 410-416
30. Simonetti RG, Liberati A, Angiolini C, et al. Treatment of hepatocellular carcinoma: a systematic review of randomized controlled trials. Ann Oncol 1997 Feb; 8 (2): 117-136
31. Yeo W, Mok TS, Zee B, et al. A randomized phase III study of doxorubicin versus cisplatin/interferon alpha-2b/ doxorubicin/fluorouracil (PIAF) combination chemotherapy for unresectable hepatocellular carcinoma. J Natl Cancer Inst 2005 Oct 19; 97 (20): 1532-1538
32. Leung TW, Patt YZ, Lau WY, et al. Complete pathological remission is possible with systemic combination chemotherapy for inoperable hepatocellular carcinoma. Clin Cancer Res 1999 Jul; 5 (7): 1676-1681
33. Yau T, Chan P, Epstein R, et al. Evolution of systemic therapy of advanced hepatocellular carcinoma. World J Gastroenterol 2008 Nov 14; 14 (42): 6437-6441
34. Gish RG, Porta C, Lazar L, et al. Phase III randomized con-trolled trial comparing the survival of patients with un-resectable hepatocellular carcinoma treated with nolatrexed or doxorubicin. J Clin Oncol 2007 Jul 20; 25 (21): 3069-3075
35. Taieb J, Bonyhay L, Golli L, et al. Gemcitabine plus ox-aliplatin for patients with advanced hepatocellular carcinoma using two different schedules. Cancer 2003 Dec 15; 98 (12): 2664-2670
36. Louafi S, Boige V, Ducreux M, et al. Gemcitabine plus oxaliplatin (GEMOX) in patients with advanced hepato-cellular carcinoma (HCC): results of a phase II study. Cancer 2007 Apr 1; 109 (7): 1384-1390
37. Chao Y, Li CP, Chau GY, et al. Prognostic significance of vascular endothelial growth factor, basic fibroblast growth factor, and angiogenin in patients with resectable hepato-cellular carcinoma after surgery. Ann Surg Oncol 2003 May; 10 (4): 355-362
38. Ho JW, Pang RW, Lau C, et al. Significance of circulating endothelial progenitor cells in hepatocellular carcinoma. Hepatology 2006 Oct; 44 (4): 836-843
39. Poon RT, Lau C, Pang R, et al. High serum vascular endo-thelial growth factor levels predict poor prognosis after radiofrequency ablation of hepatocellular carcinoma: importance of tumor biomarker in ablative therapies. Ann Surg Oncol 2007 Jun; 14 (6): 1835-1845
40. Wada H, Nagano H, Yamamoto H, et al. Expression pattern of angiogenic factors and prognosis after hepatic resection in hepatocellular carcinoma: importance of angiopoietin-2 and hypoxia-induced factor-1 alpha. Liver Int 2006 May; 26 (4): 414-423
41. Siegel AB, Cohen EI, Ocean A, et al. Phase II trial evaluating the clinical and biologic effects of bevacizumab in un-resectable hepatocellular carcinoma. J Clin Oncol 2008 Jun 20; 26 (18): 2992-2998
42. Lin AY, Brophy N, Fisher GA, et al. Phase II study of thalidomide in patients with unresectable hepatocellular carcinoma. Cancer 2005 Jan 1; 103 (1): 119-125
43. Patt YZ, Hassan MM, Lozano RD, et al. Thalidomide in the treatment of patients with hepatocellular carcinoma: a phase II trial. Cancer 2005 Feb 15; 103 (4): 749-755
44. Zhu AX, Sahani DV, di Tomaso E, et al. Sunitinib mono-therapy in patients with advanced hepatocellular carcinoma (HCC): insights from a multidisciplinary phase II study [abstract no. 4521]. 2008 ASCO Gastrointestinal Cancers Symposium; 2008 Jan 25-27; Orlando (FL).
45. Hoda D, Catherine C, Strosberg J, et al. Phase II study of sunitinib malate in adult pts (pts) with metastatic or surgically unresectable hepatocellular carcinoma (HCC) [abstract no. 267]. 2008 ASCO Gastrointestinal Cancers Symposium; 2008 Jan 25-27; Orlando (FL).
46. Faivre S, Raymond E, Boucher E, et al. Safety and efficacy of sunitinib in patients with advanced hepatocellular carcinoma: an open-label, multicentre, phase II study. Lancet Oncol 2009; 10 (8): 794-800.
47. Pfizer. Study of sunitinib malate versus sorafenib in patients with inoperable liver cancer [ClinicalTrials.gov identifier NCT00699374]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http:// www.clinicaltrials.gov [Accessed 2009 Oct 23].
48. Abou-Alfa GK, Schwartz L, Ricci S, et al. Phase II study of sorafenib in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006 Sep 10; 24 (26): 4293-4300
49. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in ad-vanced hepatocellular carcinoma. N Engl J Med 2008 Jul 24; 359 (4): 378-390
50. Cheng AL, Kang YK, Chen Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 2009 Jan; 10 (1): 25-34.
51. Zhu AX, Blaszkowsky LS, Ryan DP, et al. Phase II study of gemcitabine and oxaliplatin in combination with bev-acizumab in patients with advanced hepatocellular carcinoma. J Clin Oncol 2006 Apr 20; 24 (12): 1898-1903
52. Thomas MB, Chadha R, Glover K, et al. Phase 2 study of erlotinib in patients with unresectable hepatocellular carcinoma. Cancer 2007 Sep 1; 110 (5): 1059-1067
53. Philip PA, Mahoney MR, Allmer C, et al. Phase II study of erlotinib (OSI-774) in patients with advanced hepatocel-lular cancer. J Clin Oncol 2005 Sep 20; 23 (27): 6657-6663
54. Thomas MB, Morris JS, Chadha R, et al. Phase II trial of the combination of bevacizumab and erlotinib in patients who have advanced hepatocellular carcinoma. J Clin Oncol 2009 Feb 20; 27 (6): 843-850
55. Asnacios A, Fartoux L, Romano O, et al. Gemcitabine plus oxaliplatin (GEMOX) combined with cetuximab in patients with progressive advanced stage hepatocellular carcinoma: results of a multicenter phase 2 study. Cancer 2008 Jun 15; 112 (12): 2733-2739
56. Abou-Alfa GK, Johnson P, Knox J, et al. Final results from a phase II (PhII), randomized, double-blind study of sor-afenib plus doxorubicin (S+D) versus placebo plus doxor-ubicin (P+D) in patients (pts) with advanced hepatocellular carcinoma (AHCC) [abstract no. 128]. 2008 ASCO Gastrointestinal Cancers Symposium; 2008 Jan 25-27; Orlando (FL).
57. Zhu AX, Stuart K, Blaszkowsky LS, et al. Phase 2 study of cetuximab in patients with advanced hepatocellular carcinoma. Cancer 2007 Aug 1; 110 (3): 581-589
58. Wilhelm SM, Adnane L, Newell P, et al. Preclinical overview of sorafenib, a multikinase inhibitor that targets both Raf and VEGF and PDGF receptor tyrosine kinase signaling. Mol Cancer Ther 2008 Oct; 7 (10): 3129-3140
59. Food and Drug Administration. FDA approves sorafenib (Nexavar) for the treatment of unresectable hepatocellular carcinoma [online]. Available from URL: http://www.asco. org/ascov2/Practice+&+Guidelines/Practice+Management+ &+Reimbursement/FDA+Drug+Alerts/FDA+approves+ sorafenib+(NEXAVAR%5BR%5D) +for+the+treatment+ of+patients+with+unresectable+hepatocellular+carcinoma [Accessed 2009 Oct 22].
60. Bayer. Sorafenib as adjuvant treatment in the prevention of recurrence of hepatocellular carcinoma (STORM) [ClinicalTrials.gov identifier NCT00692770]. US National Institutes of Health, ClinicalTrials.gov [online]. Available from URL: http://www.clinicaltrials.gov [Accessed 2009 Oct 23].
61. Hoffmann K, Glimm H, Radeleff B, et al. Prospective, randomized, double-blind, multi-center, phase III clinical study on transarterial chemoembolization (TACE) combined with sorafenib versus TACE plus placebo in patients with hepatocellular cancer before liver transplantation-HeiLivCa [ISRCTN24081794]. BMC Cancer 2008; 8: 349.
62. Zhu A, Sahani D, Tomaso E. A phase II study of sunitinib in patients with advanced hepatocellular carcinoma [abstract]. Proc Am Soc Clin Oncol 2007: 4637.
63. O'Dwyer PJ, Giantonio BJ, Levy DE, et al. Gefitinib in advanced unresectable hepatocellular carcinoma: results from the Eastern Cooperative Oncology Group's Study E1203 [abstract no. 4143]. 2006 ASCO Annual Meeting; 2006 Jun 2-6; Atlanta (GA).
64. Ramanathan RK, Belani CP, Singh DA, et al. A phase II study of lapatinib in patients with advanced biliary tree and hepatocellular cancer. Cancer Chemother Pharmacol 2009 Sep; 64 4: 777-83.